These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 19367507)

  • 1. Cannabinoid CB1 receptor antagonists as potential pharmacotherapies for drug abuse disorders.
    Beardsley PM; Thomas BF; McMahon LR
    Int Rev Psychiatry; 2009 Apr; 21(2):134-42. PubMed ID: 19367507
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Current evidence supporting a role of cannabinoid CB1 receptor (CB1R) antagonists as potential pharmacotherapies for drug abuse disorders.
    Beardsley PM; Thomas BF
    Behav Pharmacol; 2005 Sep; 16(5-6):275-96. PubMed ID: 16148435
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Drug addiction.
    Justinova Z; Panlilio LV; Goldberg SR
    Curr Top Behav Neurosci; 2009; 1():309-46. PubMed ID: 21104390
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Assessment of rimonabant-like adverse effects of purported CB1R neutral antagonist / CB2R agonist aminoalkylindole derivatives in mice.
    Tai S; Vasiljevik T; Sherwood AM; Eddington S; Wilson CD; Prisinzano TE; Fantegrossi WE
    Drug Alcohol Depend; 2018 Nov; 192():285-293. PubMed ID: 30300803
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bi-directional cannabinoid signalling in the basolateral amygdala controls rewarding and aversive emotional processing via functional regulation of the nucleus accumbens.
    Ahmad T; Sun N; Lyons D; Laviolette SR
    Addict Biol; 2017 Sep; 22(5):1218-1231. PubMed ID: 27230434
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genetic or pharmacological depletion of cannabinoid CB1 receptor protects against dopaminergic neurotoxicity induced by methamphetamine in mice.
    Dang DK; Shin EJ; Mai AT; Jang CG; Nah SY; Jeong JH; Ledent C; Yamamoto T; Nabeshima T; Onaivi ES; Kim HC
    Free Radic Biol Med; 2017 Jul; 108():204-224. PubMed ID: 28363605
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cannabinoid CB
    He XH; Jordan CJ; Vemuri K; Bi GH; Zhan J; Gardner EL; Makriyannis A; Wang YL; Xi ZX
    Acta Pharmacol Sin; 2019 Mar; 40(3):365-373. PubMed ID: 29967454
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Blockade by the cannabinoid CB1 receptor antagonist, rimonabant (SR141716), of the potentiation by quinelorane of food-primed reinstatement of food-seeking behavior.
    Duarte C; Alonso R; Bichet N; Cohen C; Soubrié P; Thiébot MH
    Neuropsychopharmacology; 2004 May; 29(5):911-20. PubMed ID: 14694354
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Low brain CB1 receptor occupancy by a second generation CB1 receptor antagonist TM38837 in comparison with rimonabant in nonhuman primates: a PET study.
    Takano A; Gulyás B; Varnäs K; Little PB; Noerregaard PK; Jensen NO; Elling CE; Halldin C
    Synapse; 2014 Mar; 68(3):89-97. PubMed ID: 24293119
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cannabinoid-1 receptor (CB1R) blockers as medicines: beyond obesity and cardiometabolic disorders to substance abuse/drug addiction with CB1R neutral antagonists.
    Janero DR
    Expert Opin Emerg Drugs; 2012 Mar; 17(1):17-29. PubMed ID: 22335400
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neutral CB1 Receptor Antagonists as Pharmacotherapies for Substance Use Disorders: Rationale, Evidence, and Challenge.
    Soler-Cedeno O; Xi ZX
    Cells; 2022 Oct; 11(20):. PubMed ID: 36291128
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The endocannabinoid system and rimonabant: a new drug with a novel mechanism of action involving cannabinoid CB1 receptor antagonism--or inverse agonism--as potential obesity treatment and other therapeutic use.
    Xie S; Furjanic MA; Ferrara JJ; McAndrew NR; Ardino EL; Ngondara A; Bernstein Y; Thomas KJ; Kim E; Walker JM; Nagar S; Ward SJ; Raffa RB
    J Clin Pharm Ther; 2007 Jun; 32(3):209-31. PubMed ID: 17489873
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Acute Ethanol Inhibition of Adult Hippocampal Neurogenesis Involves CB1 Cannabinoid Receptor Signaling.
    Khatri D; Laroche G; Grant ML; Jones VM; Vetreno RP; Crews FT; Mukhopadhyay S
    Alcohol Clin Exp Res; 2018 Apr; 42(4):718-726. PubMed ID: 29417597
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Endocannabinoids promote cocaine-induced impulsivity and its rapid dopaminergic correlates.
    Hernandez G; Oleson EB; Gentry RN; Abbas Z; Bernstein DL; Arvanitogiannis A; Cheer JF
    Biol Psychiatry; 2014 Mar; 75(6):487-98. PubMed ID: 24138924
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of cannabinoid CB1 receptor antagonist rimonabant in consolidation and reconsolidation of methamphetamine reward memory in mice.
    Yu LL; Wang XY; Zhao M; Liu Y; Li YQ; Li FQ; Wang X; Xue YX; Lu L
    Psychopharmacology (Berl); 2009 Jun; 204(2):203-11. PubMed ID: 19148622
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Potential of Cannabinoid Receptor Ligands as Treatment for Substance Use Disorders.
    Galaj E; Xi ZX
    CNS Drugs; 2019 Oct; 33(10):1001-1030. PubMed ID: 31549358
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Endocannabinoid release from midbrain dopamine neurons: a potential substrate for cannabinoid receptor antagonist treatment of addiction.
    Lupica CR; Riegel AC
    Neuropharmacology; 2005 Jun; 48(8):1105-16. PubMed ID: 15878779
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cannabinoid CB(1) receptor antagonist rimonabant attenuates reinstatement of ketamine conditioned place preference in rats.
    Li F; Fang Q; Liu Y; Zhao M; Li D; Wang J; Lu L
    Eur J Pharmacol; 2008 Jul; 589(1-3):122-6. PubMed ID: 18534572
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Blockade of Nicotine and Cannabinoid Reinforcement and Relapse by a Cannabinoid CB1-Receptor Neutral Antagonist AM4113 and Inverse Agonist Rimonabant in Squirrel Monkeys.
    Schindler CW; Redhi GH; Vemuri K; Makriyannis A; Le Foll B; Bergman J; Goldberg SR; Justinova Z
    Neuropsychopharmacology; 2016 Aug; 41(9):2283-93. PubMed ID: 26888056
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neutral antagonism at the cannabinoid 1 receptor: a safer treatment for obesity.
    Meye FJ; Trezza V; Vanderschuren LJ; Ramakers GM; Adan RA
    Mol Psychiatry; 2013 Dec; 18(12):1294-301. PubMed ID: 23070073
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.